Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation …
AT Munchel, YL Kasamon, EJ Fuchs - Best practice & research Clinical …, 2011 - Elsevier
Hematopoietic stem cell transplantation provides the only potential curative option in many
patients with hematological malignancies. Finding a suitably matched donor in a timely
manner is often difficult. However, most patients have a partially HLA-mismatched (HLA-
haploidentical) first-degree relative readily available. Historically, HLA-haploidentical bone
marrow transplantation (BMT) has been considered extremely high risk due to high rates of
life-threatening graft-versus-host disease (GVHD) and non-relapse mortality (NRM) …
patients with hematological malignancies. Finding a suitably matched donor in a timely
manner is often difficult. However, most patients have a partially HLA-mismatched (HLA-
haploidentical) first-degree relative readily available. Historically, HLA-haploidentical bone
marrow transplantation (BMT) has been considered extremely high risk due to high rates of
life-threatening graft-versus-host disease (GVHD) and non-relapse mortality (NRM) …